Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]
News [14840]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
PDL-1 assay concordance
Dr Jill Walker - AstraZeneca, UK
PDL-1 assay concordance ( Dr Jill Walker - AstraZeneca, UK )
20 Oct 2016
CDK4/6 inhibition: PALOMA2 versus MONALEESA2
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
CDK4/6 inhibition: PALOMA2 versus MONALEESA2 ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
17 Oct 2016
First evidence of significant clinical activity of PD1 inhibition in metastatic...
Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University...
First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer ( Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA )
17 Oct 2016
CDK4/6 inhibitors for metastatic breast cancer
Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
CDK4/6 inhibitors for metastatic breast cancer ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
14 Oct 2016
TRAIL induced apoptosis for cancer stem cells
Prof Waleed Arafat - Alexandria Faculty of Medicine, Alexandria, Egypt
TRAIL induced apoptosis for cancer stem cells ( Prof Waleed Arafat - Alexandria Faculty of Medicine, Alexandria, Egypt )
12 Oct 2016
Who should receive combination therapy for ER positive breast cancer?
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
Who should receive combination therapy for ER positive breast cancer? ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
12 Oct 2016
Positive lessons of negative trials
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
Positive lessons of negative trials ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Drug repurposing of propranolol
Dr Pan Pantziarka - Anticancer Fund, UK
Drug repurposing of propranolol ( Dr Pan Pantziarka - Anticancer Fund, UK )
12 Oct 2016
ESMO 2016 conference highlights
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Risk of serious and fatal adverse events with sorafenib use in patients with...
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1...
Dr Omid Hamid - The Angeles Clinic, California, USA
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: ( Dr Omid Hamid - The Angeles Clinic, California, USA )
12 Oct 2016
LUME study of nintedanib finds improved PFS, but no overall survival boost
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
LUME study of nintedanib finds improved PFS, but no overall survival boost ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
12 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation